Predicting Therapeutic Drugs for Hepatocellular Carcinoma Based on Tissue-Specific Pathways

    February 2021 in “ PLoS Computational Biology ”
    Liang Yu, Meng Wang, Yang Yang, Fengdan Xu, Xu Zhang, Fei Xie, Lin Gao, Xiangzhi Li
    TLDR Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
    In this study, researchers developed a novel approach to predict therapeutic drugs for hepatocellular carcinoma (HCC) using tissue-specific pathways. They identified three potential drugs, with securinine and ajmaline showing significant inhibition of HCC cell viability and induction of apoptosis. Securinine demonstrated lower toxicity to normal liver cells, making it a promising candidate for further research. The study validated these predictions through literature analysis and experimental validation, suggesting the method's effectiveness in discovering new therapeutic options for HCC and its potential applicability to other tumors.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results